Adrenal / cortisol dysregulation
Dysregulated HPA output; normalize the adrenal axis.
Decision support, not prescription. You decide.
Candidate agents
6 agents · tap to expand▶ArgipressinEmergingArgipressin is vasopressin itself — a physiologic amplifier of the corticotroph, and the therapeutic story for cortisol dysregulation is really about blocking its V1b receptor, not giving the peptide. Treat the treatment angle as early/mechanistic.expand
Argipressin is vasopressin itself — a physiologic amplifier of the corticotroph, and the therapeutic story for cortisol dysregulation is really about blocking its V1b receptor, not giving the peptide. Treat the treatment angle as early/mechanistic.
▸Full clinical story
AVP acts on pituitary corticotroph V1b receptors to synergize with CRH, potentiating ACTH and downstream cortisol release; excessive V1b tone is proposed to sustain HPA hyperactivity. The therapeutic inference is that V1b antagonism (not agonism) should normalize an over-driven axis.
Preclinical for the therapeutic claim: the strongest direct data is a study in aged macaques where a V1b antagonist blunted the ACTH rise to hypoglycemia and to AVP injection, implicating V1b overactivation in dysregulated HPA output. The human side is mechanistic-review level — AVP co-expression in CRH neurons potentiating ACTH is well described but not a completed therapy. No human RCT shows argipressin (or V1b blockade) normalizing the adrenal axis for this indication, so 'emerging' would overstate it.
Anecdotal community signal only: vasopressin/desmopressin analogs circulate for other reasons (antidiuretic, nootropic claims), not for cortisol normalization. There is no meaningful off-label community practice using argipressin to 'reset' the adrenal axis.
Context, not a protocol: argipressin clinical dosing exists for vasodilatory shock and diabetes insipidus (unrelated to HPA modulation). No established dose targets adrenal-axis normalization; the antagonist molecules studied are investigational.
Argipressin is a potent vasoconstrictor and antidiuretic — pressor effects, hyponatremia, and fluid overload dominate its risk profile, entirely separate from any HPA rationale. Do not conflate the diagnostic/mechanistic V1b story with a usable adrenal therapy.
A biologically real lever pointing at V1b antagonism, but for cortisol dysregulation the evidence is animal-plus-mechanism. Interesting target, not a clinic-ready intervention.
- Effect of Vasopressin V1b Receptor Blockade on Activity of the Hypothalamic-Pituitary-Adrenal Axis in Old Monkeys with Depression-Like and Anxious Behavior Subjected to Stress or Injected with Vasopressin. ↗
- Arginine vasopressin (AVP): a review of its historical perspectives, current research and multifunctional role in the hypothalamo-hypophysial system. ↗
- The stress system in depression and neurodegeneration: focus on the human hypothalamus. ↗
▶OxytocinEmergingOxytocin is a plausible dampener of an over-reactive stress axis, with supportive but correlational human data and no outcome trials for cortisol dysregulation. Emerging, not established.expand
Oxytocin is a plausible dampener of an over-reactive stress axis, with supportive but correlational human data and no outcome trials for cortisol dysregulation. Emerging, not established.
▸Full clinical story
Oxytocin appears to exert an inhibitory brake on HPA output, blunting the ACTH/cortisol rise to acute psychosocial stress. Higher endogenous oxytocin tone co-tracks with a more moderated adrenal response, consistent with central attenuation of CRH/ACTH drive.
Emerging but correlational human evidence: a Trier Social Stress Test study found that individuals with higher endogenous oxytocin showed lower, more moderated ACTH/cortisol responses, and human hypothalamic reviews place oxytocin within the stress-regulatory circuitry. Both citations are observational/mechanistic, not interventional — no trial administers oxytocin and shows it corrects a defined cortisol-dysregulation phenotype, so 'emerging' is the honest ceiling.
Anecdotal community signal: intranasal oxytocin is used off-label in wellness/biohacking circles for stress, bonding, and anxiety, with users reporting acute calming and blunted stress reactivity. These reports are subjective and short-term; presented as experience, not evidence of efficacy.
Context, not a protocol: community and research use of intranasal oxytocin clusters around 20-40 IU per session, acutely before a stressor; effects are transient and dose-response for HPA endpoints is not well defined.
Intranasal delivery and dosing are non-standardized, and chronic effects on the axis are unknown — repeated dosing could theoretically alter receptor sensitivity. Watch for interactions in pregnancy and with other uterotonic or cardiovascular effects; benefit may be state- and context-dependent (social vs. non-social stress).
A credible, low-drama candidate for softening stress-driven cortisol spikes, backed by correlational human mechanistic data but not outcome trials. Reasonable to discuss as experimental; don't oversell it as a fix.
▶PACAPPreclinicalPACAP is an upstream master switch for the stress axis in animal models — mechanistically compelling for cortisol dysregulation, but entirely preclinical. Read it as target-biology, not therapy.expand
PACAP is an upstream master switch for the stress axis in animal models — mechanistically compelling for cortisol dysregulation, but entirely preclinical. Read it as target-biology, not therapy.
▸Full clinical story
PACAP drives CRH transcription in the hypothalamic paraventricular nucleus and couples stimulus to steroidogenic gene expression (StAR, 21-hydroxylase, Nr4a factors) in the adrenal cortex, sustaining corticosterone output during prolonged stress. It sits at the top of the HPA cascade, making it a candidate node for either over- or under-active axes.
Preclinical only: PACAP-deficient mice show attenuated CRH induction and adrenocortical steroidogenic transcription under restraint stress, and rat studies show PACAP gene expression is induced in PVN neurons by endotoxin/IL-1beta. These are rodent genetic and in-situ hybridization studies — no human therapeutic data exist for normalizing the adrenal axis.
Anecdotal community signal only: PACAP is discussed in peptide forums mostly around migraine and neuroprotection, occasionally 'stress resilience,' but there is no established off-label adrenal protocol and little real-world self-use for this purpose.
Context, not a protocol: no human dosing is established for HPA modulation; all quantitative work is animal central/peripheral administration in research settings.
PACAP potently triggers migraine and vasodilation in humans, which would likely be dose-limiting long before any HPA effect. Bidirectional axis effects mean naive administration could worsen rather than 'normalize' cortisol output.
High-quality target biology, zero human therapeutics. Worth understanding as a mechanism of stress-driven cortisol dysregulation; not something to deploy.
- Pituitary adenylate cyclase-activating polypeptide controls stimulus-transcription coupling in the hypothalamic-pituitary-adrenal axis to mediate sustained hormone secretion during stress. ↗
- PACAP gene expression in neurons of the rat hypothalamo-pituitary-adrenocortical axis is induced by endotoxin and interleukin-1beta. ↗
▶SpironolactoneStrongSpironolactone is the guideline first-line medical therapy for primary aldosteronism — a strong, real drug for the mineralocorticoid arm of adrenal dysregulation, not for cortisol per se.expand
Spironolactone is the guideline first-line medical therapy for primary aldosteronism — a strong, real drug for the mineralocorticoid arm of adrenal dysregulation, not for cortisol per se.
▸Full clinical story
As a mineralocorticoid-receptor antagonist it blocks aldosterone's action in the distal nephron, correcting the aldosterone-driven hypertension and hypokalemia of primary aldosteronism. Note this targets the aldosterone axis, not glucocorticoid/cortisol output directly.
Strong and guideline-backed: the Endocrine Society systematic review (95 studies, 7 RCTs) supports MR antagonism for medically managed primary aldosteronism, with spironolactone associated with better hypokalemia control and fewer/lower-dose antihypertensives than eplerenone. Surgery may beat medical therapy for blood pressure in surgically curable disease, but spironolactone is the established medical standard where surgery is not pursued.
Anecdotal community signal: spironolactone is widely used off-label for acne, hirsutism, and PCOS via its anti-androgen effect, and in that context users report skin/hair benefits — unrelated to its aldosterone indication here. This community use is real but should not be conflated with adrenal-axis management.
Context, not a protocol: primary aldosteronism medical therapy is commonly initiated around 12.5-25 mg/day and titrated (often to 25-100 mg/day) against blood pressure, potassium, and renin. Dosing is individualized and monitored.
Hyperkalemia risk rises with renal impairment and with ACE inhibitors/ARBs, NSAIDs, or potassium supplements — monitor potassium and renin. Anti-androgen effects cause gynecomastia and menstrual changes (eplerenone is the more selective alternative); it does not treat glucocorticoid excess.
Solid, evidence-based therapy for the aldosterone side of adrenal dysregulation. Correctly mapped as strong/therapeutic — just be explicit that it addresses mineralocorticoid, not cortisol, excess.
Not recommended for this condition
Shown to close the loop — the evidence points the wrong way here.
▶Seractide/ACTH (1-39)LeadStrongSynthetic ACTH is the guideline-standard provocative probe of adrenal reserve for suspected cortisol dysregulation, not a treatment. Take it seriously as a diagnostic tool.expand
Synthetic ACTH is the guideline-standard provocative probe of adrenal reserve for suspected cortisol dysregulation, not a treatment. Take it seriously as a diagnostic tool.
▸Full clinical story
Exogenous ACTH binds the adrenocortical MC2 receptor and directly drives cortisol synthesis; the peak serum cortisol after a fixed dose indexes how much reserve the gland has. A blunted rise points to primary adrenal (or chronic secondary) insufficiency, distinguishing gland-level from transient central causes.
Strong and guideline-anchored: the short Synacthen/cosyntropin stimulation test is the established dynamic assessment of adrenal insufficiency, with large real-world datasets defining thresholds and refining when it is needed. A 10-year, 1570-test cohort validated a morning-cortisol screen (<=126 nmol/L predicting non-recovery), and a 652-test audit documented over-use where a morning cortisol would have sufficed. This is diagnostic-standard evidence, not therapeutic.
Anecdotal community signal only: in longevity/peptide circles ACTH analogs are occasionally discussed for 'adrenal support,' but this conflates a diagnostic agent with therapy. There is no legitimate self-administration use case here, and clinicians use it strictly as an in-clinic test.
Context, not a protocol: standard test is 250 mcg cosyntropin IV/IM with cortisol at baseline and 30-60 min; a 1 mcg low-dose variant is used for suspected mild secondary insufficiency. Interpretation is assay- and threshold-dependent.
Recent pituitary insult (e.g., surgery within days to weeks) can yield a falsely normal test because the adrenal has not yet atrophied. Exogenous glucocorticoids and biotin/assay interference distort results; rare hypersensitivity reactions are reported during testing.
Definitive as the confirmatory test of adrenal reserve. It answers 'is the gland capable,' not 'how do I fix output' — keep it in the diagnostic column, gated behind a morning cortisol.
▶DSIP (Delta Sleep-Inducing Peptide)AnecdotalDSIP has a decades-old, thin association with glucocorticoid regulation — a curiosity-level biomarker signal for the adrenal axis, not a validated marker or therapy.expand
DSIP has a decades-old, thin association with glucocorticoid regulation — a curiosity-level biomarker signal for the adrenal axis, not a validated marker or therapy.
▸Full clinical story
Plasma DSIP-like immunoreactivity tracks with pre-dexamethasone cortisol and shifts after dexamethasone suppression, suggesting DSIP is entangled with glucocorticoid/HPA feedback. The direction of causality and any receptor-level mechanism remain undefined.
Anecdotal/very limited: the core evidence is a single small human study (34 suicide attempters vs. controls) showing elevated DSIP-like immunoreactivity in major depression and a correlation with pre-dexamethasone cortisol. This is a small correlational finding with an immunoassay of uncertain specificity — nowhere near biomarker validation, and no replication into clinical use.
Anecdotal community signal: DSIP is sold and used off-label almost entirely for sleep, with some users claiming stress/cortisol benefits that are unverified. There is essentially no community use of DSIP as a cortisol biomarker; the adrenal angle is a lab-era artifact, not current practice.
Context, not a protocol: community sleep dosing is typically low microgram-to-low-milligram subcutaneous at night; none of this is calibrated to any HPA endpoint.
Assay-based DSIP-LI does not equal a defined molecular target, so any 'HPA biomarker' framing is fragile. Research-grade product quality and identity are inconsistent; do not treat DSIP levels as clinically actionable.
Historically interesting, clinically negligible for adrenal dysregulation. Keep it filed as an unreplicated association, not a marker or lever you can act on.
Matching protocol templates
Browse all →Sleep optimization, circadian restoration, and pineal signaling
Mood normalization, sleep enhancement, and stress resilience
Neurorecovery, improved sleep, and emotional stabilization
The platform surfaces evidence, community signal and peer outcomes with enforced cautions. It never decides treatment — the licensed clinician orders labs, writes notes, and prescribes.